Aceso Life Science Announces Update on Joint Venture Formation with Jiangsu Lettall

Reuters

13 May

Aceso Life Science Announces Update on Joint Venture Formation with Jiangsu Lettall

Aceso Life Science Group Ltd. announced an update regarding the formation of a joint venture with Jiangsu Lettall. Initially disclosed on 30 March 2025, the joint venture agreement entails HTICI, a subsidiary of Aceso, and Jiangsu Lettall owning 75% and 25% of the JV Company, respectively. Recently, HTICI completed a share placement, leading to a dilution of Aceso's holding in HTICI. Consequently, HTICI's results and financial position will no longer be consolidated into Aceso's financial statements but will be accounted for separately as an associate. This update affects the company's reporting obligations regarding the joint venture agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aceso Life Science Group Ltd. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535776773"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535776773\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535776773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-13 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535776773","market":"nz","top_or_hot":-1,"title":"Aceso Life Science Announces Update on Joint Venture Formation with Jiangsu Lettall","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aceso Life Science Announces Update on Joint Venture Formation with Jiangsu Lettall\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aceso Life Science Group Ltd. announced an update regarding the formation of a joint venture with Jiangsu Lettall. Initially disclosed on 30 March 2025, the joint venture agreement entails HTICI, a subsidiary of Aceso, and Jiangsu Lettall owning 75% and 25% of the JV Company, respectively. Recently, HTICI completed a share placement, leading to a dilution of Aceso's holding in HTICI. Consequently, HTICI's results and financial position will no longer be consolidated into Aceso's financial statements but will be accounted for separately as an associate. This update affects the company's reporting obligations regarding the joint venture agreement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aceso Life Science Group Ltd. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aceso Life Science Announces Update on Joint Venture Formation with Jiangsu Lettall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAceso Life Science Announces Update on Joint Venture Formation with Jiangsu Lettall\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-13 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aceso Life Science Announces Update on Joint Venture Formation with Jiangsu Lettall\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aceso Life Science Group Ltd. announced an update regarding the formation of a joint venture with Jiangsu Lettall. Initially disclosed on 30 March 2025, the joint venture agreement entails HTICI, a subsidiary of Aceso, and Jiangsu Lettall owning 75% and 25% of the JV Company, respectively. Recently, HTICI completed a share placement, leading to a dilution of Aceso's holding in HTICI. Consequently, HTICI's results and financial position will no longer be consolidated into Aceso's financial statements but will be accounted for separately as an associate. This update affects the company's reporting obligations regarding the joint venture agreement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aceso Life Science Group Ltd. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00474","symbol_name":"信铭生命科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDLskNcF:1","article_id":"2535776773","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535776773","pubTimestamp":1747142405,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aceso Life Science Group Ltd. announced an update regarding the formation of a joint venture with Jiangsu Lettall. Initially disclosed on 30 March 2025, the joint venture agreement entails HTICI, a subsidiary of Aceso, and Jiangsu Lettall owning 75% and 25% of the JV Company, respectively. Recently, HTICI completed a share placement, leading to a dilution of Aceso's holding in HTICI. Consequently, HTICI's results and financial position will no longer be consolidated into Aceso's financial statements but will be accounted for separately as an associate. This update affects the company's reporting obligations regarding the joint venture agreement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aceso Life Science Group Ltd. published the ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00474":"信铭生命科技","BK1188":"消费信贷"},"translate_title":"Aceso Life Science宣布与江苏Lettall组建合资企业的最新情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00474":0.9},"content_text":"Aceso Life Science Announces Update on Joint Venture Formation with Jiangsu Lettall\n    \n\n        Aceso Life Science Group Ltd. announced an update regarding the formation of a joint venture with Jiangsu Lettall. Initially disclosed on 30 March 2025, the joint venture agreement entails HTICI, a subsidiary of Aceso, and Jiangsu Lettall owning 75% and 25% of the JV Company, respectively. Recently, HTICI completed a share placement, leading to a dilution of Aceso's holding in HTICI. Consequently, HTICI's results and financial position will no longer be consolidated into Aceso's financial statements but will be accounted for separately as an associate. This update affects the company's reporting obligations regarding the joint venture agreement.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aceso Life Science Group Ltd. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}